Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing innovative technologies for diagnosing and treating nervous system diseases, has announced the release of a new CEO Corner segment on its website. The segment features Brad Hauser, CEO of Autonomix, discussing Pain Awareness Month and the company's efforts to address the significant unmet need in pancreatic cancer pain.
This CEO Corner segment, now available on the Autonomix website, highlights the company's commitment to addressing critical issues in pain management, particularly in the context of pancreatic cancer. The release of this segment demonstrates Autonomix's ongoing efforts to communicate its mission and progress to stakeholders and the public.
Autonomix Medical, Inc. (NASDAQ: AMIX), un'azienda di dispositivi medici focalizzata sullo sviluppo di tecnologie innovative per la diagnosi e il trattamento delle malattie del sistema nervoso, ha annunciato il lancio di un nuovo segmento CEO Corner sul suo sito web. Il segmento presenta Brad Hauser, CEO di Autonomix, che discute del Mese della Consapevolezza del Dolore e degli sforzi dell'azienda per affrontare il significativo bisogno insoddisfatto nei dolori legati al cancro pancreatico.
Questo segmento di CEO Corner, ora disponibile sul sito web di Autonomix, sottolinea l'impegno dell'azienda nell'affrontare problemi critici nella gestione del dolore, in particolare nel contesto del cancro pancreatico. Il rilascio di questo segmento dimostra gli sforzi continui di Autonomix per comunicare la sua missione e i progressi fatti a stakeholder e al pubblico.
Autonomix Medical, Inc. (NASDAQ: AMIX), una empresa de dispositivos médicos centrada en avanzar en tecnologías innovadoras para diagnosticar y tratar enfermedades del sistema nervioso, ha anunciado el lanzamiento de un nuevo segmento CEO Corner en su sitio web. El segmento cuenta con Brad Hauser, CEO de Autonomix, hablando sobre el Mes de Concienciación sobre el Dolor y los esfuerzos de la compañía para abordar la necesidad insatisfecha significativa en el dolor del cáncer de páncreas.
Este segmento de CEO Corner, ya disponible en el sitio web de Autonomix, resalta el compromiso de la empresa con abordar cuestiones críticas en el manejo del dolor, especialmente en el contexto del cáncer de páncreas. El lanzamiento de este segmento demuestra los esfuerzos continuos de Autonomix para comunicar su misión y progreso a las partes interesadas y al público.
Autonomix Medical, Inc. (NASDAQ: AMIX), 신경계 질환의 진단 및 치료를 위한 혁신적인 기술 발전에 중점을 둔 의료 기기 회사는 웹사이트에 새로운 CEO Corner 세그먼트를 출시한다고 발표했습니다. 이 세그먼트에서는 Brad Hauser Autonomix CEO가 통증 인식의 달과 췌장암 통증에서의 상당한 충족되지 않은 요구를 해결하기 위한 회사의 노력에 대해 이야기합니다.
현재 Autonomix 웹사이트에서 제공되는 이 CEO Corner 세그먼트는 췌장암 맥락에서 통증 관리의 중요한 문제를 해결하려는 회사의 헌신을 강조합니다. 이 세그먼트의 출시는 이해관계자와 대중에게 회사의 사명과 진행 상황을 알리기 위한 Autonomix의 지속적인 노력을 보여줍니다.
Autonomix Medical, Inc. (NASDAQ: AMIX), une entreprise de dispositifs médicaux axée sur le développement de technologies innovantes pour le diagnostic et le traitement des maladies du système nerveux, a annoncé le lancement d'un nouveau segment CEO Corner sur son site web. Ce segment présente Brad Hauser, PDG d'Autonomix, qui aborde le Mois de la Sensibilisation à la Douleur et les efforts de l'entreprise pour faire face à un besoin significatif non satisfait en matière de douleur liée au cancer du pancréas.
Ce segment CEO Corner, désormais disponible sur le site d'Autonomix, souligne l'engagement de l'entreprise à traiter des questions critiques en matière de gestion de la douleur, notamment dans le contexte du cancer du pancréas. La publication de ce segment démontre les efforts continus d'Autonomix pour communiquer sa mission et ses avancées aux parties prenantes et au public.
Autonomix Medical, Inc. (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf die Weiterentwicklung innovativer Technologien zur Diagnose und Behandlung von Erkrankungen des Nervensystems konzentriert, hat die Veröffentlichung eines neuen CEO Corner Segments auf seiner Website angekündigt. In diesem Segment spricht Brad Hauser, CEO von Autonomix, über den Monat des Schmerzbewusstseins und die Bemühungen des Unternehmens, den deutlichen ungedeckten Bedarf an Schmerzen bei Bauchspeicheldrüsenkrebs zu adressieren.
Dieses CEO Corner Segment, das jetzt auf der Website von Autonomix verfügbar ist, hebt das Engagement des Unternehmens hervor, kritische Fragen im Schmerzmanagement anzugehen, insbesondere im Kontext von Bauchspeicheldrüsenkrebs. Die Veröffentlichung dieses Segments zeigt die fortlaufenden Bemühungen von Autonomix, seine Mission und Fortschritte den Interessengruppen und der Öffentlichkeit zu kommunizieren.
- Autonomix is addressing the unmet need in pancreatic cancer pain management
- The company is actively communicating with stakeholders through CEO Corner segments
- None.
THE WOODLANDS, TX, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, addressed Pain Awareness Month and what the Company is doing to address the significant unmet need in pancreatic cancer pain.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in the CEO Corner video are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in the CEO Corner video include, without limitation, the potential of the technology to treat pain associated with pancreatic cancer, to successfully enroll patients within the specific timeframe, and to complete its clinical study in pancreatic cancer pain. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What is the focus of Autonomix Medical's latest CEO Corner segment?
Who is featured in Autonomix Medical's (AMIX) new CEO Corner segment?
Where can investors find Autonomix Medical's (AMIX) latest CEO Corner segment?
What is Autonomix Medical's (AMIX) primary focus as a medical device company?
